Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Agenus Inc (NASDAQ:AGEN)

Delayed Data
As of Dec 09
 -0.05 / -1.15%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Agenus, Inc. is a biotechnology company, which is focused on the development and commercialization of technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its core technology portfolio consists of Saponin platform and Heat Shock Protein platform. The company within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by its licensees in numerous vaccines under development in clinical trials, some as advanced as phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus and tuberculosis. Agenus within its HSP Platform is developing its recombinant series and prophage series vaccines. The company's HerpV, a therapeutic vaccine candidate from the recombinant series, which contains QS-21 Stimulon, has been tested in a phase 1 clinical trial for the treatment of genital herpes. Agenus was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Contact Information

Agenus, Inc.
3 Forbes Road
Lexington Massachusetts 02421-7305
P:(781) 674-4400
Investor Relations:



Individual stakeholders5.59%
Other institutional34.09%
Mutual fund holders12.25%

Top Executives

Garo H. ArmenChairman & Chief Executive Officer
Christine M. KlaskinChief Financial & Accounting Officer
Robert B. SteinPresident-Research & Development
Alexander R. DuncanChief Technology Officer
Karen Higgins ValentineSecretary, Chief Compliance Officer & VP